Understanding underage vaping today starts with a clear view of what products are shaping the market. A growing share of vaping products, including those most commonly associated with underage vaping, are sold outside the regulated system, without consistent age verification, product standards, or compliance oversight. When products operate outside the regulatory framework, public health safeguards, including those designed to limit underage appeal and access, are not consistently applied. Addressing underage use effectively requires acknowledging these real-world dynamics and ensuring enforcement against illicit products plays a role alongside regulation. Learn more at: ow.ly/ySsS50Z9JgZ #PreventUnderageUse #DataDriven #TobaccoHarmReduction

Conversations about youth vaping should begin with the most current data. As noted in our recent comments to FDA, national survey results show that youth vaping has declined significantly since its 2019 peak and is now at the lowest level in a decade. Youth prevention remains a critical priority. At the same time, a shared understanding of today’s data helps ensure the conversation is grounded in the current public health landscape. Learn more at: ow.ly/3GkX50Z8cMc #YouthPrevention #DataDriven #TobaccoHarmReduction

Progress in tobacco harm reduction depends on rigorous science and open dialogue. That’s why we share our research and engage with scientists, the public health community, and regulators—inviting review and conversation about our work. Explore our latest research and learn more at sciences.altria.com. #AltriaScience #Research #ScientificEngagement #HarmReduction

Visit Altria Science to explore our recent publications at: ow.ly/ElzZ50YIXkm #Science #Research #Publications #RegulatoryScience #HarmReduction

Science matters—especially when it comes to harm reduction. Jeff Edmiston shares how leading high‑quality clinical studies, grounded in Good Clinical Practices, helps build the scientific evidence behind smoke‑free products to provide adults who smoke with reduced-risk alternatives. #AltriaSciences #ScientistSpotlight #Movingbeyondsmoking

For our latest research updates and study highlights, follow Altria Sciences on LinkedIn. Science, data, and progress—one place.

Today at the FDLI Annual Conference, Paige Magness will join the panel “Next Gen Nicotine? Lessons from CTP’s Nicotine Pouch Pilot.” This timely conversation will cover FDA CTP’s nicotine pouch pilot program, key lessons learned, and recent authorizations. The discussion will also include discussions on the implications for APPH, SE exemptions, and supplemental PMTAs, and whether elements of the pilot could inform future approaches for ENDS and other nicotine products. #AltriaSciences #HarmReduction #Movingbeyondsmoking

Today at the Food & Drug Law Institute Annual Conference, Dr. Mohamadi Sarkar will join the panel “Risk, Reward, and Responsibility—From Data to Dialogue on Nicotine Communication,” alongside leading experts in science and public health. The discussion will explore how scientific evidence informs nicotine risk messaging, how communication may evolve, and how to better educate adults who smoke while avoiding youth appeal. #AltriaSciences #HarmReduction #Movingbeyondsmoking

Science is at the core of how we approach tobacco harm reduction. That’s why we follow a rigorous scientific framework—grounded in FDA guidance—to evaluate smoke-free products from product design to individual risk assessment and overall population impact. Our work spans toxicology, clinical research, population science, and modeling, and we aim to be transparent by inviting scientific review and dialogue. Learn more about our scientific framework: ow.ly/LTAS50YIYqt #AltriaScience #HarmReduction #PublicHealth #Innovation

Next week Altria will be attending and participating on panels at the 2026 FDLI Annual Conference in Washington, DC. The FDLI Annual Conference is a leading forum for the food and drug law community, bringing together experts from government, industry, academia, and advocacy to examine the legal, regulatory, compliance, and policy issues shaping FDA-regulated products, including tobacco and nicotine. We look forward to engaging in discussions on the evolving regulatory landscape for tobacco and nicotine products and connecting with stakeholders across the FDLI community. #AltriaSciences #HarmReduction #Movingbeyondsmoking

Looking for deeper context on our research and scientific priorities? Join the conversation on LinkedIn for the latest from Altria Sciences.

Science matters—especially when it comes to harm reduction. Jeff Edmiston shares his career path to Altria and how leading high‑quality clinical studies, grounded in Good Clinical Practices, helps build the scientific evidence behind smoke‑free products to support adult smokers who would otherwise continue to smoke. #AltriaSciences #ScientistSpotlight #Movingbeyondsmoking

Science is at the core of our approach to harm reduction. Our research focuses on generating rigorous, transparent evidence across key areas, including: - Analytical science to understand the physical and chemical properties of products - Pre‑clinical science to assess biological and toxicological effects - Clinical science to evaluate exposure and potential risk in adult users - Population science to understand real‑world behavior and outcomes - Modeling & simulation to inform product development and regulatory decision‑making Together, this science supports the development and evaluation of authorized smoke‑free products designed to help adults who smoke move away from combustible cigarettes. Learn more: sciences.altria.com #AltriaSciences #ScientistSpotlight #Movingbeyondsmoking

Prohibition often shifts demand into illicit markets. Harm reduction takes a different approach—meeting adult smokers where they are with science‑based alternatives that can meaningfully reduce risk. It’s a pathway proven across public health challenges and one that supports better outcomes for adults who would otherwise continue to smoke. Learn more at ow.ly/l9j050YIWVK. #AltriaSciences #HarmReduction #Movingbeyondsmoking

Today at #ATNF2026, Paige Magness will join a panel on regulatory reforms and the PMTA pathway—an important discussion for advancing harm reduction while supporting informed consumer choice in a well‑regulated marketplace. #AltriaSciences #HarmReduction #Movingbeyondsmoking

We’re pleased to share that Sydana Rogers Hollins will be joining a panel at the American Tobacco & Nicotine Forum (ATNF) to discuss lessons learned from FDA’s pilot program on nicotine pouch authorizations. #AltriaScience #HarmReduction #Movingbeyondsmoking

Looking forward to joining conversations at the American Tobacco & Nicotine Forum (ATNF) as leaders across science, regulation and public health gather to discuss the future of tobacco and nicotine. #AltriaScience #HarmReduction #Movingbeyondsmoking

We’re sharing more of the science behind our work—study highlights, research updates, and data‑driven insights. 👉 Follow Altria Sciences on LinkedIn to stay connected.

We’re committed to openly sharing the results of our research. Altria’s Science website is regularly updated with data we present or publish, and we actively engage with the scientific community through conferences, meetings, and other forums. Learn more at sciences.altria.com #Transparency #HarmReduction #SmokeFreeFuture #MovingBeyondSmoking

Adult nicotine consumers deserve options—products that satisfy, evolve with expectations, and can potentially reduce risk. They also deserve accurate information to make informed choices. We’re committed to delivering innovative smoke-free products and brands across e-vapor, oral nicotine pouches, and heated tobacco—helping adult smokers move towards a smoke-free future. Learn more: altria.com #MovingBeyondSmoking #SmokeFreeFuture #Innovation #HarmReduction